- Global Pharma News & Resources

Cancer Vaccines Market Is Generating Revenue of $12,814 million by 2023, at CAGR 17.7% Growth Rate


The global cancer vaccines market was valued at $4,073 million in 2016, and is projected to reach at $12,814 million by 2023, growing at a CAGR of 17.7% from 2017 to 2023. The recombinant cancer vaccines segment accounted for one-third share of the global market in 2016.

Vaccines include antigenic components, which strengthens an individuals immune system by developing adaptive immunity to prevent morbidity from infections. Cancer vaccine is a type of immunotherapy that boost the bodys natural defenses by stimulating the immune system to recognize and cure cancerous cells.

Download Free Report Sample @

The global market is driven by rise in prevalence of HPV infections and related cancer, increase in administration of prophylactic cancer vaccines, surge in investments & findings in the development of cancer vaccines, and launch of novel cancer vaccines in the market. However, longer timelines required for manufacturing a single vaccine restrain the development of new vaccines; thereby, hampering the market growth. In addition, high monetary inputs for the development of cancer vaccines decrease their adoption in the market; thereby, hampering the market growth.

The cervical cancer segment accounted for maximum market revenue in 2016, and is anticipated to maintain its dominant position during the forecast period, owing to the increase in number of people suffering from human papilloma virus (HPV) infections, which causes approximately 70% of cervical cancers globally. In addition, high prevalence of cervical, prostate, lungs, and breast cancer among adults propel the market growth. However, prostate cancer is growing at the highest CAGR of 18.6% from 2017 to 2023, owing to the increase in demand for Provenge (prostate cancer vaccine) along with the increase in number of prostate cancer vaccines in the pipeline.

The recombinant cancer vaccines segment dominated the global market in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the large number of approved cancer vaccines developed using recombinant technology such as Cervarix, Gardasil, and Recombivax HB. The therapeutic cancer vaccines segment is anticipated to register the highest growth rate during the forecast period, owing to the increase in transition from prophylactic cancer vaccines to therapeutic cancer vaccines.

Get a purchase Enquiry @

The adult cancer vaccine segment dominated the end use market, accounting for about fifth-eighths share of the global market in 2016, due to the increase in incidence of HPV infections, breast cancers, and prostate cancers among adults. Moreover, active government participation for provision of vaccination to all children has augmented the market growth.

Asia-Pacific witnessed the highest growth rate for cancer vaccines in 2016, and is expected to continue this trend throughout the forecast period. This is attributed to large population base, rise in incidence of HPV infection related cancers & other cancer cases, healthcare infrastructural development, and huge market potential. Moreover, the introduction of novel preventive, therapeutic, and adult cancer vaccines in the market along with the increasing focus by key players in the emerging markets has fueled the growth of the industry.

The key players operating in the vaccines market have adopted product launch as their key developmental strategy and focus on launching innovative products to cater to the consumer requirements and strengthen their market shares.

The major companies profiled Are:

Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.

The other key players Are:

Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Galena Biopharma, Emergent Biosolutions, Prokarium, and ImmunoBiology Ltd.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

Get more information:

Similar Reports:

Preoperative Surgical Planning Software Market

Osseointegration Implants Market

Cholera Vaccine Market

South Korea ECG Market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.


David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
Market Pulse:
Follow Us on LinkedIn:

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

Editor Details

Last Updated: 11-Feb-2020